Blossomhill Therapeutics Inc (BLSM)

$20.86 -0.65 (-3.02%)
Market Cap 639.23M
Revenue (ttm) 0.00
Net Income (ttm) -60.56M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 148,900
Avg Vol N/A
Day's Range N/A - N/A
Shares Out 30.64M
Stochastic %K 57%
Beta N/A
Analysts Strong Sell
Price Target $32.20

Company Profile

BlossomHill Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops small molecule medicines that address medical needs in cancer treatment. Its pipeline includes BH-30643, an OMNI-EGFR inhibitor in clinical development for advanced EGFR-mutant non-small cell lung cancer (NSCLC), BH-501284, and BH-30236, a macrocyclic CLK (Cdc2-like kinase) inhibitor being evaluated in patients with relapsed or refractory acute myeloid leukemia (R/R AML) and higher-risk myelodysplastic syndrome...

Industry: Biotechnology
Sector: Healthcare
Phone: (858) 732-3880
Address:
10255 Science Center Drive, Suite 200, San Diego, United States
YouVSYou
YouVSYou Sep. 11 at 10:41 PM
YVY Weekend Setup Board $CRBP Monday obesity data with major ATM risk $BLSM cancer data Monday night and the cleanest paper $LPTH record revenue with a $110.9M backlog $LTRX post earnings continuation setting up $ALMS $9.7M insider accumulation but needs a chart reclaim Catalysts filings dilution and levels all checked Full setups posted in YVY Community 💫 Which one runs first
0 · Reply
IN0V8
IN0V8 Sep. 1 at 4:23 PM
$BLSM Opportunity JP Morgan starts coverage with overweight rating; PT $28 Guggenheim initiates coverage with buy rating Guggenheim initiates coverage with PT $30 H.C. Wainwright initiates coverage with buy rating H.C. Wainwright initiates coverage with PT $35 Leerink Partners initiates coverage with PT $36 Leerink Partners starts coverage with outperform rating
0 · Reply
Quantumup
Quantumup Sep. 1 at 1:07 PM
JPMorgan🏁 $BLSM and said -- We are initiating coverage of BlossomHill Therapeutics (BLSM) with an Overweight rating and a Dec-2027 price target of $28. $AVBP $CGEM MRK DSNKY BDTX ORIC AZN JNJ Here's what JPMorgan went on to say: https://x.com/Quantumup1/status/2094774045099139272?s=20
0 · Reply
mktrdr59
mktrdr59 Aug. 31 at 11:44 PM
$BLSM made a pretty sharp pullback, but volume not too heavy. Tested support at the Aug 26 low & the .618 retracement of the Aug 20 - Aug 28 rally.
0 · Reply
JFais
JFais Aug. 28 at 1:11 PM
Chat Rundown for Friday: $RVMD - great discussion on Rasonque's label and how chemo-ineligible is defined for treating 1L (very permissive language) $BHVN - seems like several skeptics getting back on board here, immediate cash needs solved (runway for degraders to shine) $GUBRA - under the radar Danish obesity name appearing in our Real-Time trades channel (UCN2 as a promising muscle-sparing adjunct mechanism) $BLSM - another recent IPO just starting to break out. CEO is the inventor of Crizotinib, then Lorlatinib and Repotrectinib. OMNI-EGFR inhibitor could have fast path to market in the C797S population, also shows efficacy in T790M and triple mutants in preclinical Lastly, great debate on Sell Rules (when to hold patiently & when to trim - valuation gets excessive, other attractive ideas on radar & avoiding higher risk binaries among other factors) $XBI
0 · Reply
justiceforb_85
justiceforb_85 Aug. 27 at 7:50 PM
$BLSM very nice movement. hopefully this doubles toward the end of the year with clear accelerated approval pathway through the FDA.
0 · Reply
Jamiston42
Jamiston42 Aug. 25 at 4:50 PM
$BLSM this is going to explode, trust me.
1 · Reply
justiceforb_85
justiceforb_85 Aug. 19 at 11:37 PM
$BLSM look forward to possible accelerated approval for BH-30643.
0 · Reply
RTPRwire
RTPRwire Aug. 18 at 11:39 AM
$BLSM is active on FDA approval following a Globe Newswire release. BlossomHill Therapeutics receives FDA Fast Track designation for BH-30643, a macrocyclic EGFR inhibitor for advanced EGFR C797S-positive NSCLC. RTPR pushed this release out to users at 7:00:00 AM ET
0 · Reply
theflynews
theflynews Aug. 10 at 3:18 PM
Opening Day: Biotech names lead week’s IPO activity - $BLSM - https://thefly.com/BLSM
0 · Reply
Latest News on BLSM
BlossomHill Therapeutics to Present at the 8th Annual RAS-Targeted Drug Development Summit & H.C. Wainwright 28th Annual Global Investment Conference

Sep 3, 2026, 7:00 AM EDT - 10 days ago

BlossomHill Therapeutics to Present at the 8th Annual RAS-Targeted Drug Development Summit & H.C. Wainwright 28th Annual Global Investment Conference

Guggenheim starts BlossomHill Therapeutics with a Buy on pipeline potential

2026-09-01T11:05:48.000Z - 12 days ago

Guggenheim starts BlossomHill Therapeutics with a Buy on pipeline potential

BlossomHill Therapeutics initiated with an Outperform at Leerink

2026-09-01T11:05:44.000Z - 12 days ago

BlossomHill Therapeutics initiated with an Outperform at Leerink

BlossomHill Therapeutics to Present Updated Data from Ongoing Phase 1/2 SOLARA Trial of its Macrocyclic OMNI-EGFR™ Inhibitor, BH-30643, in EGFR-mutant NSCLC at the 2026 World Conference on Lung Cancer

Sep 1, 2026, 7:00 AM EDT - 12 days ago

BlossomHill Therapeutics to Present Updated Data from Ongoing Phase 1/2 SOLARA Trial of its Macrocyclic OMNI-EGFR™ Inhibitor, BH-30643, in EGFR-mutant NSCLC at the 2026 World Conference on Lung Cancer

BlossomHill Therapeutics initiated with an Outperform at LifeSci Capital

2026-09-01T10:20:14.000Z - 12 days ago

BlossomHill Therapeutics initiated with an Outperform at LifeSci Capital

BlossomHill Therapeutics initiated with a Buy at Guggenheim

2026-09-01T10:15:08.000Z - 12 days ago

BlossomHill Therapeutics initiated with a Buy at Guggenheim

BlossomHill Therapeutics initiated with a Buy at H.C. Wainwright

2026-09-01T10:10:27.000Z - 12 days ago

BlossomHill Therapeutics initiated with a Buy at H.C. Wainwright

BlossomHill Therapeutics initiated with an Overweight at JPMorgan

2026-09-01T09:30:15.000Z - 13 days ago

BlossomHill Therapeutics initiated with an Overweight at JPMorgan

BlossomHill Therapeutics receives fast track designation for BH-30643 from FDA

2026-08-18T11:10:13.000Z - 26 days ago

BlossomHill Therapeutics receives fast track designation for BH-30643 from FDA

BlossomHill Therapeutics Announces FDA Fast Track Designation for BH-30643, a Macrocyclic OMNI-EGFR™ Inhibitor for the Treatment of Advanced EGFR C797S-positive NSCLC

Aug 18, 2026, 7:00 AM EDT - 26 days ago

BlossomHill Therapeutics Announces FDA Fast Track Designation for BH-30643, a Macrocyclic OMNI-EGFR™ Inhibitor for the Treatment of Advanced EGFR C797S-positive NSCLC

BlossomHill Therapeutics Stock (BLSM) Fails to Shine After $150M U.S. IPO

2026-08-07T19:07:26.000Z - 5 weeks ago

BlossomHill Therapeutics Stock (BLSM) Fails to Shine After $150M U.S. IPO

BMY JPM

BlossomHill Therapeutics opens at $15.75, IPO priced at $16.00

2026-08-07T16:35:37.000Z - 5 weeks ago

BlossomHill Therapeutics opens at $15.75, IPO priced at $16.00

BlossomHill Therapeutics 9.375M share IPO priced at $16.00

2026-08-07T03:00:30.000Z - 5 weeks ago

BlossomHill Therapeutics 9.375M share IPO priced at $16.00

BlossomHill Therapeutics Announces Pricing of Upsized $150 Million Initial Public Offering

Aug 6, 2026, 8:07 PM EDT - 5 weeks ago

BlossomHill Therapeutics Announces Pricing of Upsized $150 Million Initial Public Offering

BlossomHill Therapeutics Slides: Corporate presentation

Aug 6, 2026, 7:00 AM EDT - 5 weeks ago

BlossomHill Therapeutics Slides: Corporate presentation

BlossomHill Therapeutics 7.81M share IPO price range $15.00-$17.00

2026-08-04T09:05:35.000Z - 5 weeks ago

BlossomHill Therapeutics 7.81M share IPO price range $15.00-$17.00

Latigo, BlossomHill launch US IPOs as biotech listings rebound

Aug 3, 2026, 8:25 AM EDT - 5 weeks ago

Latigo, BlossomHill launch US IPOs as biotech listings rebound

LTGO

BlossomHill Therapeutics Registration statement: Registration filing

Aug 3, 2026, 8:00 AM EDT - 5 weeks ago

BlossomHill Therapeutics Registration statement: Registration filing

BlossomHill Therapeutics Registration statement: Registration filing

Jul 17, 2026, 8:00 AM EDT - 1 month ago

BlossomHill Therapeutics Registration statement: Registration filing

Cancer therapies biotech BlossomHill Therapeutics files for a $100 million IPO

Jul 17, 2026, 12:51 AM EDT - 1 month ago

Cancer therapies biotech BlossomHill Therapeutics files for a $100 million IPO

BlossomHill Therapeutics IPO Registration Document (S-1)

Jul 16, 2026, 8:13 PM EDT - 1 month ago

BlossomHill Therapeutics IPO Registration Document (S-1)

YouVSYou
YouVSYou Sep. 11 at 10:41 PM
YVY Weekend Setup Board $CRBP Monday obesity data with major ATM risk $BLSM cancer data Monday night and the cleanest paper $LPTH record revenue with a $110.9M backlog $LTRX post earnings continuation setting up $ALMS $9.7M insider accumulation but needs a chart reclaim Catalysts filings dilution and levels all checked Full setups posted in YVY Community 💫 Which one runs first
0 · Reply
IN0V8
IN0V8 Sep. 1 at 4:23 PM
$BLSM Opportunity JP Morgan starts coverage with overweight rating; PT $28 Guggenheim initiates coverage with buy rating Guggenheim initiates coverage with PT $30 H.C. Wainwright initiates coverage with buy rating H.C. Wainwright initiates coverage with PT $35 Leerink Partners initiates coverage with PT $36 Leerink Partners starts coverage with outperform rating
0 · Reply
Quantumup
Quantumup Sep. 1 at 1:07 PM
JPMorgan🏁 $BLSM and said -- We are initiating coverage of BlossomHill Therapeutics (BLSM) with an Overweight rating and a Dec-2027 price target of $28. $AVBP $CGEM MRK DSNKY BDTX ORIC AZN JNJ Here's what JPMorgan went on to say: https://x.com/Quantumup1/status/2094774045099139272?s=20
0 · Reply
mktrdr59
mktrdr59 Aug. 31 at 11:44 PM
$BLSM made a pretty sharp pullback, but volume not too heavy. Tested support at the Aug 26 low & the .618 retracement of the Aug 20 - Aug 28 rally.
0 · Reply
JFais
JFais Aug. 28 at 1:11 PM
Chat Rundown for Friday: $RVMD - great discussion on Rasonque's label and how chemo-ineligible is defined for treating 1L (very permissive language) $BHVN - seems like several skeptics getting back on board here, immediate cash needs solved (runway for degraders to shine) $GUBRA - under the radar Danish obesity name appearing in our Real-Time trades channel (UCN2 as a promising muscle-sparing adjunct mechanism) $BLSM - another recent IPO just starting to break out. CEO is the inventor of Crizotinib, then Lorlatinib and Repotrectinib. OMNI-EGFR inhibitor could have fast path to market in the C797S population, also shows efficacy in T790M and triple mutants in preclinical Lastly, great debate on Sell Rules (when to hold patiently & when to trim - valuation gets excessive, other attractive ideas on radar & avoiding higher risk binaries among other factors) $XBI
0 · Reply
justiceforb_85
justiceforb_85 Aug. 27 at 7:50 PM
$BLSM very nice movement. hopefully this doubles toward the end of the year with clear accelerated approval pathway through the FDA.
0 · Reply
Jamiston42
Jamiston42 Aug. 25 at 4:50 PM
$BLSM this is going to explode, trust me.
1 · Reply
justiceforb_85
justiceforb_85 Aug. 19 at 11:37 PM
$BLSM look forward to possible accelerated approval for BH-30643.
0 · Reply
RTPRwire
RTPRwire Aug. 18 at 11:39 AM
$BLSM is active on FDA approval following a Globe Newswire release. BlossomHill Therapeutics receives FDA Fast Track designation for BH-30643, a macrocyclic EGFR inhibitor for advanced EGFR C797S-positive NSCLC. RTPR pushed this release out to users at 7:00:00 AM ET
0 · Reply
theflynews
theflynews Aug. 10 at 3:18 PM
Opening Day: Biotech names lead week’s IPO activity - $BLSM - https://thefly.com/BLSM
0 · Reply
justiceforb_85
justiceforb_85 Aug. 8 at 3:19 AM
$BLSM added. BH-30643 with compelling activity in post-osimertinib setting, including C797S and T790M NSCLC. Closest competitor is VRN110755 but they are studying their drug outside the US and will therefore have a much lower chance of US approval.
1 · Reply